Alivus Life Sciences Limited (NSE:ALIVUS)

India flag India · Delayed Price · Currency is INR
883.50
+22.00 (2.55%)
Jan 23, 2026, 3:29 PM IST
-21.30%
Market Cap108.44B
Revenue (ttm)25.12B
Net Income (ttm)5.44B
Shares Out122.74M
EPS (ttm)44.23
PE Ratio19.97
Forward PE17.68
Dividend5.00 (0.58%)
Ex-Dividend DateSep 1, 2025
Volume208,914
Average Volume62,671
Open887.00
Previous Close861.50
Day's Range861.50 - 909.40
52-Week Range819.00 - 1,251.00
Beta0.08
RSI49.64
Earnings DateJan 22, 2026

About Alivus Life Sciences

Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health,... [Read more]

Sector Healthcare
Founded 2001
Employees 2,203
Stock Exchange National Stock Exchange of India
Ticker Symbol ALIVUS
Full Company Profile

Financial Performance

In 2024, Alivus Life Sciences's revenue was 23.87 billion, an increase of 4.54% compared to the previous year's 22.83 billion. Earnings were 4.86 billion, an increase of 3.13%.

Financial Statements